Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of 1 of the following indolent or aggressive B-cell non-Hodgkin's lymphoma (NHL) subtypes:
• * Grade 1-3 follicular lymphoma
• * Mantle cell lymphoma
• * Small lymphocytic lymphoma
• * Diffuse large B-cell lymphoma
• * Diffuse mixed cell lymphoma
• * Marginal zone lymphoma
• Relapsed or refractory CD20-positive disease
• Measurable disease
• Must have received ≥ 1 but \< 4 prior standard chemotherapy regimens
• No Burkitt's lymphoma or precursor B-lymphoblastic lymphoma
• No CNS lymphoma
• PATIENT CHARACTERISTICS:
• Performance status
• Karnofsky 60-100%
• Life expectancy
• At least 6 months
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 75,000/mm\^3
• Hemoglobin \> 7 g/dL
• Hepatic
• AST or ALT \< 2 times upper limit of normal (unless due to primary disease)
• Bilirubin ≤ 2 mg/dL
• Renal
• Creatinine ≤ 2.0 mg/dL
• Cardiovascular
• LVEF ≥ 50% by MUGA and/or 2-D echocardiogram
• No history of New York Heart Association class II-IV cardiac disease
• No congestive heart failure
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No known HIV positivity
• No uncontrolled active bacterial, viral, or fungal infection
• No other serious disease that would preclude study participation
• No other primary malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Recovered from prior immunotherapy
• Prior immunotherapy, including rituximab or other monoclonal antibody, allowed
• Chemotherapy
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy and recovered
• No prior doxorubicin (or equivalent anthracycline) at a cumulative dose \> 400 mg/m\^2
• No other concurrent chemotherapy
• Endocrine therapy
• Nonsteroidal hormones for nonlymphoma-related conditions (e.g., insulin for diabetes) allowed
• No concurrent corticosteroids except for a transient inflammatory reaction (i.e., skin rash or hives)
• Radiotherapy
• Recovered from prior radiotherapy
• No concurrent radiotherapy
• Surgery
• More than 4 weeks since prior major surgery (other than diagnostic surgery) and recovered
• Other
• No other concurrent antitumor agents
• No other concurrent investigational agents